Skip to main content

Advertisement

ADVERTISEMENT

News

FDA alert
FDA Alert
04/22/2024
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug...
04/22/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Bharati Kochar
Conference Coverage
04/10/2024
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about...
04/10/2024
Advances in Inflammatory Bowel Disease Network
News
04/05/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Investigators sought to determine the effects of hormone replacement therapy on disease activity among postmenopausal women with IBD.
Investigators sought to determine the effects of hormone replacement therapy on disease activity among postmenopausal women with IBD.
Investigators sought to...
04/05/2024
Advances in Inflammatory Bowel Disease Network
News
03/20/2024

Jolynn Tumolo

Jolynn Tumolo
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week...
03/20/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
03/06/2024
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a...
03/06/2024
Advances in Inflammatory Bowel Disease Network
News
02/23/2024

Jolynn Tumolo

Jolynn Tumolo
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory...
02/23/2024
Advances in Inflammatory Bowel Disease Network
Conference Coverage
02/20/2024
How patients perceive the severity of their ulcerative colitis is affected by the frequency of bowel urgency episodes and accidents, researchers reported at the American College of Gastroenterology Postgraduate Course.
How patients perceive the severity of their ulcerative colitis is affected by the frequency of bowel urgency episodes and accidents, researchers reported at the American College of Gastroenterology Postgraduate Course.
How patients perceive the...
02/20/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
02/15/2024
Researchers investigated a new tool that could help predict primary sclerosing cholangitis, a chronic liver disease that is strongly associated with IBD.
Researchers investigated a new tool that could help predict primary sclerosing cholangitis, a chronic liver disease that is strongly associated with IBD.
Researchers investigated a new...
02/15/2024
Advances in Inflammatory Bowel Disease Network
News
02/12/2024
Investigators examined the prognosis and clinicopathological features of Crohn’s disease-associated colorectal cancer (CRC) compared with sporadic CRC.
Investigators examined the prognosis and clinicopathological features of Crohn’s disease-associated colorectal cancer (CRC) compared with sporadic CRC.
Investigators examined the...
02/12/2024
Advances in Inflammatory Bowel Disease Network
News
02/05/2024
Recent findings highlighted the relationship between subcutaneous infliximab concentrations and favorable therapeutic outcomes among patients with IBD.
Recent findings highlighted the relationship between subcutaneous infliximab concentrations and favorable therapeutic outcomes among patients with IBD.
Recent findings highlighted the...
02/05/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement